Welcome to our dedicated page for Novocure news (Ticker: NVCR), a resource for investors and traders seeking the latest updates and insights on Novocure stock.
NovoCure Limited develops and commercializes Tumor Treating Fields therapy for solid tumors through wearable medical devices including Optune Gio, Optune Lua and Optune Pax. News about NVCR centers on product approvals, reimbursement decisions, launch activity and the use of TTFields in glioblastoma, pancreatic cancer, non-small cell lung cancer and pleural mesothelioma.
Company updates also cover clinical programs such as PANOVA, LUNAR and KEYNOTE studies, quarterly financial results, research and clinical-study spending, and commercialization across the United States, Europe, Japan and other markets where the company has approved products.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Novocure (NASDAQ: NVCR) has announced that the results of its LUNAR phase 3 clinical trial in metastatic non-small cell lung cancer (NSCLC) will be unveiled at the 2023 ASCO Annual Meeting in Chicago from June 2 to June 6. This randomized, open-label study evaluates the safety and efficacy of Tumor Treating Fields (TTFields) combined with immunotherapies for patients progressing after platinum-based treatments. The trial has shown a statistically significant improvement in overall survival with the addition of TTFields. The data will be presented on June 6 at 11:09 a.m. CDT by Ticiana Leal, M.D., and includes among ten abstracts focused on TTFields therapy at the ASCO meeting. An investor event will also be hosted on the same day to discuss these findings.
Novocure (NASDAQ: NVCR) announced that 27 presentations on Tumor Treating Fields (TTFields) will be showcased at the AACR Annual Meeting 2023 from April 14 to 19 in Orlando, Florida. Research highlights include a comprehensive safety dataset of over 25,000 patients with glioblastoma, demonstrating the broad applicability and safety of TTFields therapy. A systematic review indicated improved overall survival in newly diagnosed glioblastoma patients treated with TTFields. Preclinical studies suggest that TTFields enhance the effectiveness of chemotherapy and may offer new treatment avenues for spinal metastasis and ovarian cancer. These findings underscore the potential of TTFields across various solid tumors, reinforcing Novocure's commitment to advancing cancer treatment.